证券代码：688626 证券简称：翔宇医疗 公告编号：2025-055 河南翔宇医疗设备股份有限公司 根据河南翔宇医疗设备股份有限公司（以下简称"公司"）全资子公司河南 瑞贝塔医疗科技有限公司（以下简称"瑞贝塔"）的建设发展规划和实际生产经 营需要，瑞贝塔计划向金融机构申请总额不超过人民币 40,000.00 万元的贷款。 公司拟为瑞贝塔提供担保总额度不超过 40,000.00 万元的不可撤销连带责任担 保，具体条款届时以签订的合同为准。本次担保无反担保。 | | 被担保人名称 | | 河南瑞贝塔医疗科技有限公司 | | --- | --- | --- | --- | | | 本次担保金额 | 40,000.00 万元 | | | 担保对象 | 实际为其提供的担保余额 | 0.00 万元 | | | | 是否在前期预计额度内 | 是 □否 | ☑不适用：_________ | | | 本次担保是否有反担保 | 是 ☑否 | □不适用：_________ | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0.00 | | --- | --- | | 截至本公告日上市公司及其控股 | | | 子公司对 ...

河南翔宇医疗设备股份有限公司（以下简称"公司"）第三届监事会第八次 会议于 2025 年 11 月 14 日在公司会议室以现场结合通讯的方式召开。会议通知 于同日送达各位监事，全体监事一致同意豁免本次会议通知时间要求。本次会议 应出席监事 3 人，实际出席监事 3 人。会议由监事会主席李治锋先生主持。会议 的召开及表决程序符合有关法律、行政法规、部门规章和《公司章程》的规定。 二、监事会会议审议情况 经与会监事投票表决，本次会议审议并通过了以下议案： （一）审议通过《关于为全资子公司提供担保的议案》 经审议，监事会认为：公司本次为全资子公司提供担保，是为了满足全资子 公司建设发展规划和实际生产经营的资金需求，符合公司经营发展需要；该担保 对象为公司全资子公司，担保风险可控，不会损害公司利益；本次担保事项符合 法律法规及《公司章程》的有关规定。 证券代码：688626 证券简称：翔宇医疗 公告编号：2025-054 河南翔宇医疗设备股份有限公司 第三届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 ...

河南翔宇医疗设备股份有限公司 2025 年第二次临时股东大会会议资料 证券代码：688626 证券简称：翔宇医疗 河南翔宇医疗设备股份有限公司 2025 年第二次临时股东大会 会议资料 2025 年 11 月 1 河南翔宇医疗设备股份有限公司 2025 年第二次临时股东大会会议资料 河南翔宇医疗设备股份有限公司 2025 年第二次临时股东大会会议须知 河南翔宇医疗设备股份有限公司（以下简称"公司"）为维护全体股东的合 法权益，保证股东大会的正常秩序和议事效率，确保大会的顺利进行，根据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司股东大会规则》及《公司章程》、《股 东大会议事规则》及中国证券监督管理委员会、上海证券交易所的有关规定，公 司特制定本会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请给予配合。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，务请 出席大会的股东或其代理人或其他出席者准时到达会场签到确认参会资格。会议 开始后，会议登记应当终 ...

Core Insights - The brain engineering sector is leading the market with a rise of 1.05% [1] Company Performance - Aipeng Medical saw a significant increase of 7.51% [1] - Innovation Medical experienced a rise of 4.41% [1] - Century Huatong increased by 3.41% [1] - Chengyitong, Xiangyu Medical, and Sanbo Brain Science all rose by over 2% [1]

Core Viewpoint - The company reported a slight increase in total revenue by 6.00% year-on-year, but net profit significantly decreased by 42.89% year-on-year, primarily due to increased R&D expenses of 126 million yuan, which rose by 20.15% year-on-year [2]. Group 1: Financial Performance - Total revenue increased by 6.00% year-on-year [2]. - Net profit decreased by 42.89% year-on-year [2]. - R&D expenses amounted to 126 million yuan, reflecting a year-on-year increase of 20.15% [2]. Group 2: R&D Focus - The company emphasizes research and development as a key driver for product innovation and upgrades [2]. - The strategic R&D direction focuses on applications in rehabilitation medicine, including brain-machine interfaces, exoskeleton robots, and artificial intelligence (AI) [2]. - The establishment of the Rehabilitation Robot Laboratory and Sun-BCI Lab for brain science indicates a commitment to advancing brain-machine interface technology [2]. - A significant portion of R&D investment is directed towards areas directly or indirectly related to brain-machine interface technology [2].

Core Viewpoint - The A-share market is experiencing a surge in brain-computer interface concept stocks, driven by the approval of a domestically developed implantable wireless brain-computer interface system entering the special review process by the National Medical Products Administration of China, marking a significant step in the commercialization of this technology in China [1] Group 1: Stock Performance - Aipeng Medical saw a nearly 12% increase in stock price, with a total market value of 40.03 billion and a year-to-date increase of 80.63% [2] - Century Huatong and Innovative Medical both rose over 7%, with market values of 141.1 billion and 10.5 billion respectively, and year-to-date increases of 269.65% and 198.87% [2] - Botao Biological increased by over 5%, with a market value of 6.62 billion and a year-to-date increase of 95.06% [2] - Xiangyu Medical rose over 4%, with a market value of 8.33 billion and a year-to-date increase of 78.19% [2] - Other notable stocks include Sanbo Brain Science, Saily Medical, Dineike, Taihe Technology, and Chengyi Tong, all showing increases of over 3% [1][2] Group 2: Industry Development - The implantable wireless brain-computer interface system developed by Shanghai Ladder Medical Technology Co., Ltd. is the first invasive brain-computer interface product to enter the "green channel" for innovative medical devices in China, indicating a key advancement from clinical validation to market access in this cutting-edge technology field [1]

Core Viewpoint - The brain-computer interface concept stocks experienced a surge in early trading, with Aipeng Medical rising over 10%, followed by gains in Innovative Medical, Beikang, Xiangyu Medical, and Century Huato [1] Company Summary - Aipeng Medical saw a significant increase of over 10% in its stock price [1] - Innovative Medical, Beikang, Xiangyu Medical, and Century Huato also followed with upward movements in their stock prices [1]

Core Insights - On November 11, brokerages issued target prices for listed companies a total of 21 times, with notable increases in target prices for Century Huatong, ZTE Corporation, and Zhuhai Smelter Group, showing increases of 50.48%, 47.02%, and 34.74% respectively, across the gaming, communication equipment, and industrial metals sectors [1][2]. Target Price Increases - Century Huatong received a target price of 26.50 yuan, reflecting a target price increase of 50.48% [2]. - ZTE Corporation's target price was set at 60.13 yuan, indicating a 47.02% increase [2]. - Zhuhai Smelter Group's target price reached 20.40 yuan, with a 34.74% increase [2]. - Other companies with significant target price increases include Jinlei Co. (30.79%), Changan Automobile (30.29%), and Sanhua Intelligent Control (29.84%) [2]. Brokerage Recommendations - The top companies recommended by brokerages on November 11 include Zhonglian Heavy Industry, Xinbao Co., and Sany Heavy Industry, each receiving two brokerage ratings [3]. - Zhonglian Heavy Industry had a closing price of 8.44 yuan, while Xinbao Co. closed at 15.30 yuan, and Sany Heavy Industry at 20.91 yuan [3]. Rating Adjustments - Nanjing Steel Group's rating was upgraded from "Hold" to "Buy" by Zhongtai Securities on November 11 [4]. - A total of 14 companies received first-time coverage from brokerages, with Zhejiang Energy Power rated "Hold" and Zhonggu Logistics rated "Hold" as well [5]. Newly Covered Companies - Newly covered companies include Zhejiang Energy Power (rated "Hold"), Zhonggu Logistics (rated "Hold"), and Longxin General (rated "Outperform") [5]. - Other companies receiving first-time ratings include Yifeng Pharmacy (rated "Outperform") and Haier Smart Home (rated "Buy") [5].

Investment Rating - The investment rating for the company is "Outperform the Market" [4] Core Insights - The company has shown steady revenue growth, with a revenue of 537 million yuan in the first three quarters of 2025, representing a 6% increase year-on-year. However, the net profit attributable to the parent company has decreased by 40.09% to 44 million yuan due to increased R&D and marketing expenditures [1][2] - The company is significantly increasing its investment in brain-computer interface (BCI) technology, having established a comprehensive product matrix and five major brain science laboratories. The company plans to launch multiple new products by the end of 2025 [2] - The gross profit margin has slightly increased to 67.19%, while the total expense ratio has risen significantly, indicating a focus on R&D and market promotion [1] Financial Performance Summary - Revenue for 2025 is projected at 802 million yuan, with a year-on-year growth rate of 7.9%. The net profit attributable to the parent company is expected to be 100 million yuan, reflecting a slight decrease of 2.6% [3][22] - The company’s earnings per share (EPS) is forecasted to be 0.63 yuan in 2025, with a price-to-earnings (PE) ratio of 83.7x [3][22] - The company’s operating margin is projected to be 7.4% in 2025, with a return on equity (ROE) of 4.8% [3][22]

Industry Overview - Rehabilitation devices are defined as medical equipment or assistive tools used in rehabilitation to assess, train, and treat patients, helping them improve functionality and recover bodily functions or compensate for deficiencies [1] - The rehabilitation device industry can be categorized into rehabilitation medical aids, rehabilitation therapy equipment, rehabilitation training devices, and assessment instruments [1] Industry Chain Analysis - The upstream of the rehabilitation medical device industry mainly consists of raw materials and software systems, with raw materials being the core element affecting product quality and manufacturing efficiency [2] - The midstream involves the production of rehabilitation assessment instruments, training devices, therapy equipment, and other rehabilitation devices [2] - The downstream consumer segment primarily includes elderly, chronic disease, and disabled groups [2][5] Industry Development History - The Chinese rehabilitation device industry has gone through three stages: initial phase (1980-1989), transformation phase (1990-2011), and rapid growth phase (2012-present), with significant policy support and market expansion in the latter phase [7][8] Policy Background - Recent national policies have promoted high-level standardization and integration of rehabilitation devices with technologies like AI, IoT, and 5G, creating favorable conditions for high-quality industry transformation [10][11] Current Industry Status - The number of registered rehabilitation device products in China has seen explosive growth since 2019, with projections indicating 1,167 registrations by 2024 [14] - The market size for rehabilitation devices in China is expected to reach approximately 21.1 billion yuan in 2024, driven by an aging population and increasing chronic diseases [15] - Rehabilitation aids dominate the market, accounting for 82.15% of the total market size in 2024 [17] - The elderly care segment is projected to account for about 67% of the application structure in 2024 [18] Competitive Landscape - The competitive landscape of the rehabilitation device industry shows a concentration of core manufacturing enterprises in eastern coastal provinces like Jiangsu, Guangdong, and Shandong, while central and western regions focus on raw material supply [21] - The top three companies in the rehabilitation device market by share in 2024 are Kefu Medical, Yuyue Medical, and Xiangyu Medical, with market shares of 6.47%, 6.18%, and 3.51% respectively [24] Future Development Outlook - By 2030, the market size of the rehabilitation device industry is expected to exceed 47 billion yuan, driven by the aging population and increased demand for rehabilitation services [26] - The industry is predicted to grow at a compound annual growth rate (CAGR) of around 14% from 2025 to 2030 [26] Industry Trends - The rehabilitation device industry is experiencing a trend towards smart technology and product diversification, with the integration of AI, IoT, and 3D printing technologies [28] - The aging population and the rise in chronic diseases are expected to sustain the growth of rehabilitation demand, supported by favorable policies and market expansion [28]